Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Anavex Life Sciences stock | $5.4

Own Anavex Life Sciences stock in just a few minutes.

Fact checked

Anavex Life Sciences Corp is a biotechnology business based in the US. Anavex Life Sciences shares (AVXL) are listed on the NASDAQ and all prices are listed in US Dollars. Anavex Life Sciences employs 16 staff and has a market cap (total outstanding shares value) of USD$346.1 million.

How to buy shares in Anavex Life Sciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Anavex Life Sciences. Find the stock by name or ticker symbol: AVXL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Anavex Life Sciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$5.4, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Anavex Life Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Anavex Life Sciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Anavex Life Sciences share price

Use our graph to track the performance of AVXL stocks over time.

Anavex Life Sciences shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$5.4
52-week rangeUSD$2.2 - USD$7.69
50-day moving average USD$5.3479
200-day moving average USD$4.7498
Wall St. target priceUSD$13
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.598

Buy Anavex Life Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Anavex Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Anavex Life Sciences price performance over time

Historical closes compared with the close of $5.4 from 2020-12-31

1 week (2021-01-11) -3.57%
1 month (2020-12-18) -10.74%
3 months (2020-10-16) 11.57%
6 months (2020-07-17) 21.90%
1 year (2020-01-17) 63.64%
2 years (2019-01-18) 196.70%
3 years (2018-01-18) 73.08%
5 years (2016-01-15) 34.66%

Anavex Life Sciences financials

Gross profit TTM USD$0
Return on assets TTM -61.12%
Return on equity TTM -122.52%
Profit margin 0%
Book value $0.411
Market capitalisation USD$346.1 million

TTM: trailing 12 months

Shorting Anavex Life Sciences shares

There are currently 6.7 million Anavex Life Sciences shares held short by investors – that's known as Anavex Life Sciences's "short interest". This figure is 9.5% down from 7.4 million last month.

There are a few different ways that this level of interest in shorting Anavex Life Sciences shares can be evaluated.

Anavex Life Sciences's "short interest ratio" (SIR)

Anavex Life Sciences's "short interest ratio" (SIR) is the quantity of Anavex Life Sciences shares currently shorted divided by the average quantity of Anavex Life Sciences shares traded daily (recently around 1.3 million). Anavex Life Sciences's SIR currently stands at 5.11. In other words for every 100,000 Anavex Life Sciences shares traded daily on the market, roughly 5110 shares are currently held short.

However Anavex Life Sciences's short interest can also be evaluated against the total number of Anavex Life Sciences shares, or, against the total number of tradable Anavex Life Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anavex Life Sciences's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Anavex Life Sciences shares in existence, roughly 110 shares are currently held short) or 0.1162% of the tradable shares (for every 100,000 tradable Anavex Life Sciences shares, roughly 116 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Anavex Life Sciences.

Find out more about how you can short Anavex Life Sciences stock.

Anavex Life Sciences share dividends

We're not expecting Anavex Life Sciences to pay a dividend over the next 12 months.

Have Anavex Life Sciences's shares ever split?

Anavex Life Sciences's shares were split on a 1:4 basis on 7 October 2015. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Anavex Life Sciences shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Anavex Life Sciences shares which in turn could have impacted Anavex Life Sciences's share price.

Anavex Life Sciences share price volatility

Over the last 12 months, Anavex Life Sciences's shares have ranged in value from as little as $2.2 up to $7.69. A popular way to gauge a stock's volatility is its "beta".

AVXL.US volatility(beta: 0.74)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anavex Life Sciences's is 0.7412. This would suggest that Anavex Life Sciences's shares are less volatile than average (for this exchange).

Anavex Life Sciences overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase II clinical trials to treat Parkinson's disease; and preclinical clinical trials to treat Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Its preclinical drug candidates include ANAVEX 3-71, a central nervous system (CNS)-penetrable mono-therapy to treat Alzheimer's and Parkinson's diseases; ANAVEX 1-41, a sigma-1 agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site